ARAlexis Revet

Alexis Revet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexis Revet has a total of 215 co-authors. Here are the top co-authors by number of shared publications:

  • Jean-Philippe Raynaud

    10 shared publications
  • Johannes Hebebrand

    Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, LVR Klinikum Essen, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

    8 shared publications
  • Paul Klauser

    Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

    8 shared publications
  • François Montastruc

    Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital, Toulouse, France

    5 shared publications
  • Eric Bui

    Caen University Hospital, Caen, France

    4 shared publications
  • Paul Klauser

    Division of Child and Adolescent Psychiatry, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

    4 shared publications

Latest Publications

  • Clinical practices in ADHD management across Europe: findings from the ESCAP research academy survey

    by Héloïse Young, Alexis Revet, Julie Hagstrøm, Burçin Özlem Ates, Astrid Brænden, Markella Grigoriou, Irina Jarvers, Moa Jederström, Lucie Jurek, Konstantinos Kotsis, et al.

    In several European countries, national clinical guidelines for the management of ADHD are lacking. In others, guidelines are outdated or do not address more detailed aspects of care, such as medication titration procedures or specific recommendations for school adjustments. Perceptions of the appropriateness of treatment, which influence the delivery of care for ADHD, are shaped by sociocultural aspects. Consequently, practices in the management of ADHD are expected to substantially vary across Europe. To better understand current practices in both pharmacological and non-pharmacological management of ADHD, as well as clinicians’ perceptions of treatment appropriateness, we conducted an online survey among European qualified child and adolescent (neuro)psychiatrists and general psychiatrists or trainees involved in the care of children and adolescents with ADHD. The survey was developed and implemented by the European Society for Child and Adolescent Psychiatry (ESCAP) Research Academy, with input from the European ADHD Guidelines Group (EAGG). It was completed by 1,441 clinicians of varying seniority from 23 European countries. The findings provide updated insights into ADHD management across Europe and highlight three key unmet needs. First, several clinically relevant areas lack sufficient evidence, including how to personalise treatment and identify practical predictors of treatment response. Second, some existing evidence has not yet been adequately translated into clinical guidelines or routine practice, particularly regarding comparative treatment effects and dose–response relationships relevant to medication titration. Third, some respondents reported needs that are already addressed in existing international guidelines, suggesting that language barriers may limit access to guidance and underscoring the importance of developing country-specific recommendations in local languages. Overall, this survey - to our knowledge the largest of its kind conducted in Europe - provides valuable information to inform future clinical guidelines, research priorities, and health policy. It also informs future training programmes aimed at reducing bias in the perception and delivery of ADHD treatment.

  • Consommation de psychotropes et de soins en santé mentale à la suite d'un événement traumatique de masse : une approche pharmaco-épidémiologique centrée sur l'enfant et l'adolescent à partir du Système National des Données de Santé

    by Alexis Revet

    Contexte : Les données sur l'utilisation des soins de santé mentale en population pédiatrique après une attaque terroriste sont relativement limitées. De plus, plusieurs études ont mis en évidence la complexité et les variations temporelles dans l'utilisation des services de santé mentale et des psychotropes après un attentat. L'objectif principal de cette thèse est d'évaluer l'impact à court et moyen terme chez les enfants et les adolescents de l'attaque terroriste du 14 juillet 2016 à Nice en termes d'utilisation des ressources de santé mentale, à partir des données du Système National des Données de Santé (SNDS), l'une des plus importantes bases de données médico-administratives du monde. Méthodes et résultats : Nous avons d'abord réalisé une revue systématique (PROSPERO CRD42021225296) pour décrire l'utilisation du SNDS pour la recherche dans le champ de la santé mentale. Au total, 152 études, sélectionnées parmi 15 265 articles examinés lors de la phase de screening, ont été analysées en détail. Cette revue systématique a mis en évidence une exploitation relativement faible de la base de données du SNDS dans le domaine de la recherche en santé mentale au regard des possibilités qu'elle offre, avec un faible nombre d'études méthodologiques et un net retard dans certains domaines comme les études épidémiologiques ou d'économie de la santé, et dans des populations spécifiques, en particulier les enfants et les adolescents. Nous avons identifié trois études qui ont utilisé le SNDS pour examiner l'impact de trois catastrophes : la canicule d'août 2003, la tempête Xynthia de 2010 et une catastrophe industrielle. Cependant, ces trois études étaient centrées sur les adultes et les données chez les enfants et les adolescents font défaut. De plus, il n'y avait pas d'étude portant sur des attentats terroristes et ces études analysaient uniquement la consommation de psychotropes et ne considéraient pas la consommation globale de soins (étude numéro 1). Nous avons ensuite mené une étude quasi-expérimentale avec utilisation de séries témoins pour estimer l'impact à court et moyen terme sur la consommation de psychotropes dans le département des Alpes-Maritimes, après l'attentat au camion-bélier du 14 juillet 2016 à Nice. Nous avons utilisé des modèles de type autoregressive integrated moving average (ARIMA) pour réaliser une analyse de séries temporelles interrompues trimestrielles du 1er janvier 2012 au 31 décembre 2018, afin d'examiner la consommation de psychotropes dans les Alpes-Maritimes par rapport à trois départements témoins. Entre 2012 et 2018, nous avons observé une diminution globale de la prévalence d'utilisation des médicaments psychotropes chez les adultes, et chez les enfants et adolescents, dans les départements témoins uniquement, contrastant avec une augmentation (+8%) dans les Alpes-Maritimes, particulièrement marquée en 2017 et 2018. Le seul écart visuellement détectable entre les valeurs prédites et observées concernait l'incidence d'utilisation des psychotropes chez les enfants et les adolescents (modèle ARIMA (0,1,1) x (1,1,0)4 avec un test de Box-Ljung non significatif [khi² = 11,343 ; df = 24 ; p = 0,986]). Cette différence visuelle n'était pas statistiquement significative pour le changement de pas (estimation ± erreur standard [SE] = 0,187 ± 0,228 ; p = 0,413) ou le changement de pente (estimation ± SE = 0,020 ± 0,056 ; p = 0,724) (étude numéro 2). Enfin, nous avons développé le protocole de l'étude PaEDiatric IMPact of terrorist AttaCks in general populaTion (PEDIMPACT) visant à évaluer l'impact à court et moyen terme chez les enfants et les adolescents de l'attaque terroriste de Nice du 14 juillet 2016 sur l'utilisation globales des ressources en santé mentale, c'est-à-dire : 1) l'utilisation de médicaments psychotropes ; 2) les hospitalisations liées à la santé mentale ; et 3) les visites ambulatoires (étude numéro 3).

  • Open Access

    Melatonin prescription in children: a study of the POMMEs cohorts

    by Auriane Gaye, Anthony Caillet, Alexis Revet, Justine Benevent

  • The 2025 ESCAP Research Academy workshop: advancing mechanistic insights and early intervention strategies for psychological trauma

    by Alexis Revet, Koen Bolhuis, Héloïse Young, Andrea Danese, Isabelle M. Mansuy, Vera Clemens, Eric Bui, Jörg Fegert, Assia Riccioni, Julie Rolling, et al.

    The 2025 ESCAP Research Academy Workshop in Strasbourg focused on the impact of psychological trauma on the brain, emphasising mechanistic insights and early intervention strategies. Prior to the ESCAP Congress, this event aims at supporting the next generation of clinician-scientists in child and adolescent mental health (CAMH). Under the guidance of coordinators Alexis Revet and Paul Klauser, nineteen fellows from 13 countries engaged in comprehensive discussions. Keynote speakers Andrea Danese, Isabelle Mansuy, Vera Clemens, and Eric Bui, offered critical insights into trauma mechanisms and interventions. Using the "world café" model, participants developed a European-wide trauma questionnaire, illustrating international collaboration. The workshop, which was supported by the ESCAP Academic division, successfully integrated academic and clinical insights with personal development. The next workshop is scheduled to take place in 2027 in Athens.

  • Open Access

    Relationships between adverse childhood experiences, oxidative stress, and development of mental disorders: A systematic review of animal and human studies

    by Antoine Stocker, Basilio Giangreco, Alexis Revet, Luis Alameda, Eric Bui, David Bürgin, Vera Clemens, Samuele Cortese, Daniel S. Schechter, Marc Schmid, et al.


  • Top Cited Papers
    Open Access

    The use of antipsychotics in the treatment of catatonia: a systematic review

    by Maximilien Redon, Jordan Virolle, François Montastruc, Simon Taïb, Alexis Revet, Julien Da Costa, Etienne Very

    Background: Catatonia in psychotic patients presents unique challenges. While antipsychotics are the cornerstone of schizophrenia treatment, their use in catatonic patients is sometimes discouraged for fear of worsening the signs. Reports on the successful use of second-generation antipsychotics have been published. We conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines to describe the outcomes of antipsychotic-treated catatonic events. Methods: We searched Medline and Web of Science databases from 2000 to 2023 using search terms including “catatonia” and “antipsychotic agents” for all original peer-reviewed articles, including clinical trials, observational studies, and case-reports. We included antipsychotic-treated catatonic events and extracted data on patient characteristics, pharmacological context, agent involved, and treatment outcomes for each antipsychotic trial. Results: After screening 6,219 records, 79 full-text articles were included. Among them, we identified 175 antipsychotic trials (in 110 patients). Only 41.1% of the patients benefited from a previous benzodiazepine trial. Antipsychotic use was considered beneficial in 60.0% of the trials, neutral in 29.1%, and harmful in 10.9%. Trials tended to be reported as beneficial for amisulpride, clozapine, and risperidone, equivocal for aripiprazole and olanzapine, and mostly detrimental for haloperidol and quetiapine. Psychotic disorders were the most common underlying etiology (65.8%). Conclusions: Antipsychotics could be an option in the treatment of catatonia in psychotic patients. However, with few exceptions, we found non-beneficial outcomes with all second-generation antipsychotics in varying proportions in this largest review to date. Although olanzapine is widely used, it is associated with mitigated reported outcomes.


  • What clinical analysis of antipsychotic-induced catatonia and neuroleptic malignant syndrome tells us about the links between these two syndromes: A systematic review

    by Jordan Virolle, Maximilien Redon, François Montastruc, Simon Taïb, Alexis Revet, Vuk Zivkovic, Julien Da Costa, Etienne Very


  • Invited editorial: Suicidality in child and adolescents facing challenging times

    by Antoine Stocker, Alexis Revet

    Suicide and its associated conditions, such as suicidal ideation or self-harm behavior, unfortunately remain a major public health issue. This is especially the case in youth, as suicide is the sec...


  • Open Access

    Comparative cardiovascular side effects of medications for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis

    by Alice Lannes, Luis C Farhat, Cinzia Del Giovane, Andrea Cipriani, Alexis Revet, Samuele Cortese

    Introduction Pharmacotherapy is an important component of the multimodal treatment of attention-deficit/hyperactivity disorder (ADHD). Cardiovascular safety of medications for ADHD is of concern from a clinical and public health standpoint. We aim to conduct a network meta-analysis (NMA) comparing the effects of available medications for ADHD on blood pressure (diastolic and systolic), heart rate and ECG parameters over the short-term and long-term treatment. Methods and analysis Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines for protocols and NMAs will be followed. We will include parallel group or cross-over randomised controlled trials (RCTs) conducted in patients with a primary diagnosis of ADHD (no age limits). We will search an extensive number of electronic databases (including MEDLINE, CINAHL, CENTRAL, EMBASE, ERIC, PsycINFO, OpenGrey, Web of Science) from their inception and contact study authors/drug manufacturers to gather relevant unpublished information. No language restrictions will be applied. The main outcomes (assessed at 12 weeks, 26 weeks and 52 weeks) will be: (1) change in diastolic and systolic blood pressure (mm Hg); (2) change in heart rate, measured in beats/min; (3) change in any available ECG parameters. We will conduct random effects of NMA using standardised mean differences with 95% CIs for continuous outcomes and ORs with 95% CIs for dichotomous outcomes. We will use the Cochrane risk of bias tool-version 2 to assess the risk of bias of included RCTs and the Confidence In Network Meta-Analysis tool to evaluate the confidence of evidence contributing to each network estimate. Sensitivity analyses will investigate effects at different dose regimens. Ethics and dissemination No institutional review board approval will be necessary. The results of this systematic review and meta-analysis will be presented at national and international conferences and published in peer-reviewed journals. PROSPERO registration number CRD42021295352.